“We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion’s CEO. “Don’s track record of strategic and operational financial leadership, coupled with his extensive experience as ...
The "Crown" logo, PanOxyl and Blue Lizard are registered trademarks of Crown Laboratories, Inc. SkinPen and StriVectin are registered trademarks of Bellus Medical, LLC and StriVectin Operating Company ...
Nashville-based aesthetics biotech company Revance Therapeutics announced Wednesday that a planned merging with Johnson City, ...
AbbVie (ABBV) stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm posted better ... In addition, AbbVie sees aesthetics revenues through 2029 to be in a high-single ...
Newport Beach-based Elevai last month underwent a company reorganization, including switching parent companies and changing the company’s name from Elevai Labs to PMGC Holdings Inc.
The complaint outlined that AbbVie provided travel tickets and hotel accommodation for extravagant pleasure trips under the guise of conferences-Aesthetics and Anti-aging Medicine World Congress 2024, ...
They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...
A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...
Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...
In 2019, Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some aggressive cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback